SenesTech Inc pivoted its strategy to focus on rodent birth control, achieving $770,000 Q2 2026 revenue with a 76.6% gross margin while targeting e-commerce growth to offset losses.
SenesTech CEO Michael Edell purchased 2,000 shares worth $1,740 as the stock trades near its 52-week low, amidst reports of record revenue but ongoing cash burn concerns.
SenesTech CEO Michael Edell discusses the company's unique rodent birth control niche and business model shifts toward e-commerce. He addresses recent stock underperformance, attributing it to early s
SenesTech CEO Michael Edell purchased 1,000 shares at $1.21 per share, increasing his direct ownership to 6,000 shares according to a Form 4 filing.
SenesTech CEO Michael Edell purchased 1,000 shares for $1,429, raising his direct holdings to 5,000. The company reported a 2% revenue increase and improved gross margins in Q1 2026.
SenesTech CEO Michael Edell purchased 1,000 shares, increasing holdings to 5,000, while the company reported 2% revenue growth and expanded market reach for its Evolve Rodent Birth Control products.
SenesTech has appointed Jack Karabees as Executive Vice President of Sales to lead expansion of its rodent fertility control products, targeting growing demand for sustainable pest control solutions.
SenesTech reported Q1 2026 revenue of $493,000, a 2% year-over-year increase driven by Evolve products, despite net losses widening to $2.1 million due to higher operating expenses.
SenesTech CFO Thomas C. Chesterman was granted 75,000 stock options at $1.65 per share, vesting quarterly over three years, per Form 4 filing.
SenesTech Inc holds a 3.00 institutional confidence score in the Chemicals industry, with institutional ownership surging 204.77% QoQ to 34.07%, led by James Simons.
SenesTech disclosed that CEO Michael Edell was granted 263,288 stock options with a $1.47 exercise price, vesting over three years starting June 2026.
SenesTech Inc. CEO Michael Edell acquired 1,000 common shares at $1.55 per share on June 8, 2026, raising his direct ownership to 4,000 shares per Form 4 filing.
SenesTech Inc has restructured its board and appointed Michael Edell as its new CEO, aiming to scale revenue for the company.
SenesTech gains attention after a hantavirus outbreak on a cruise ship underscores the need for its nonlethal rodent fertility control solutions, such as ContraPest, as alternatives to traditional che
SenesTech Inc. CEO Michael Edell purchased 3,000 shares totaling $5,013 in open-market transactions on May 14 and 15, 2026, increasing his direct ownership.
SenesTech Inc reported a 2% Q1 revenue increase to $493,000 and appointed Michael Edell as new President and CEO, despite a net loss of $2.1 million.
SenesTech Inc. reported record Q1 2026 revenue and gross margins driven by its shift to in-house Amazon e-commerce management and new leadership, highlighting strong subscription momentum and municipa
SenesTech Inc has appointed Michael Edell as its new President and CEO effective May 6, 2026. His compensation package includes a $360,000 base salary and a 5% equity option grant contingent on shareh
SenesTech Inc. has appointed Michael Edell as president and CEO, effective Tuesday. Edell previously served as interim COO and helped shift the company's focus to direct-to-consumer channels for its E
SenesTech Inc. appointed Michael Edell as President and CEO effective May 6, 2026, to scale revenue channels and expand sales opportunities. The company also appointed Matthew Szot as new Board Chair
ChemBrief